Clinical trial country use share vs Antibody-drug conjugate trial starts in China
In 2023, clinical trial country use share in China was 15%; antibody-drug conjugate trial starts was 120.
Change the pair
Compare different indicators
The series
Over time
China, annual figures, spaced by time . Different units, drawn on separate scales . Read the values, not the heights.
Clinical trial country use share
Unit: % · 2 observations
Antibody-drug conjugate trial starts
Unit: count · 6 observations
Shared periods
Side by side
Only one period is published for both series in China as annual figures on the same basis. Comparing anything else would mean comparing different periods.
Provenance
Where these numbers come from
Clinical trial country use share
Percentage of total clinical trial country uses accounted for by a given region.
2 observations charted in China · source organisations: IQVIA
Antibody-drug conjugate trial starts
Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.
6 observations charted in China · source organisations: ClinicalTrials.gov
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring